By EVOBYTE Your partner for the digital lab
In a digital lab, data moves quickly from instruments to software, from software to reports, and sometimes from the lab into clinical or regulatory records. That speed is valuable, but it also creates a simple question: can your team prove what changed, when it changed, who changed it, and why? That is the purpose of an audit trail. Across FDA guidance, EU Annex 11, and ICH E6(R3), an audit trail is described as a secure, computer-generated, time-stamped record or set of metadata that allows the reconstruction of events around an electronic record.
In practical terms, an audit trail is the recorded history of a piece of data. It should show the original entry, later changes, the user involved, the date and time, and in many settings the reason for the change as well. For a laboratory manager, this matters because it replaces guesswork with evidence. If a result is corrected, a sample is reclassified, or a document is replaced, the system should be able to show exactly what happened without relying on memory, email chains, or screenshots.
Why audit trails matter in the digital lab
Audit trails are especially important when laboratory data supports regulated work. FDA guidance says audit trails help protect the authenticity, integrity, and, when appropriate, confidentiality of electronic records. The same guidance says they must be kept at least as long as the related records and be available for agency review. In clinical trial settings, this is not theoretical. EMA guidance notes that inspectors may need audit trails on case report form data, histories of user access changes, and datasets that make those records reviewable. EMA also states that eTMF systems should capture user, date, and time details for creating, uploading, deleting, and changing documents.
From a regulatory point of view, the real question is usually not whether a platform is called a LIMS, ELN, CTMS, or eTMF. The real question is whether that platform creates, modifies, stores, or transfers regulated electronic records. That is why audit trail expectations typically extend across LIMS, ELNs, instrument and chromatography software, quality systems, manufacturing systems, EDC or eCRF platforms, eTMF repositories, and CTMS-linked datasets. This is a practical inference from Part 11 and Annex 11, which focus on the record and the risk rather than the software label. In clinical research, the scope is broad: ICH E6(R3) describes data acquisition tools to include CRFs, wearables, electronic health records, and laboratory systems, while FDA guidance on electronic source data focuses on keeping data reliable and traceable from electronic source to regulatory submission. EMA also warns that common spreadsheet tools used for trial oversight can be risky because they often lack a true audit trail.
The regulatory reason is clear. Authorities do not ask for audit trails because they like extra paperwork. They ask for them because trustworthy decisions depend on trustworthy records. EU Annex 11 defines audit trails as a way to reconstruct events in computerized systems, and the same guidance frames good data through ALCOA+, meaning records should be attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available. If a lab cannot show who changed a potency result or when a controlled document was replaced, it becomes much harder to defend the data during an inspection, an investigation, or a product review.
Audit trail and data lineage in the digital lab
This is where data lineage becomes important. Audit trail and data lineage are closely related, but they are not the same thing. Data lineage, often called data provenance, describes where data came from, how it moved, and how it changed over time. OECD guidance says labs need to understand their data flows across the data life cycle, and Government of Canada guidance describes provenance as the history of data, including its origins, how it was created, and how it has been used.
A simple way to think about it is this: an audit trail usually explains events inside one system, while data lineage connects the whole path across systems. Imagine a result is generated on an instrument, reviewed in instrument software, approved in a LIMS, transferred into a clinical database, and then used in a report. The audit trail shows the events inside each step. Data lineage shows the full route from source to final use. In a well-designed digital lab, both are needed. The audit trail answers, “Who changed this record?” Data lineage answers, “Where did this record come from, and what else did it affect?” Together they make investigations faster, reporting more credible, and integrations safer.
In the end, an audit trail should never be treated as a technical add-on. In a digital lab, it is a core control for trust, speed, and compliance. When labs build audit trail and data lineage into LIMS workflows, instrument integrations, and reporting processes from the start, they spend less time reconstructing history before inspections and more time using data with confidence. For many organizations, the biggest gain comes not from buying one more standalone system, but from designing connected systems so traceability survives every handoff.
Further reading
FDA, Guidance for Industry: Computerized Systems Used in Clinical Trials. (fda.gov)
International Council for Harmonisation, ICH E6(R3) Module 1.1.
European Commission, Annex 11: Computerised Systems. (health.ec.europa.eu)
European Medicines Agency, Guideline on the content, management and archiving of the clinical trial master file. (ema.europa.eu)
OECD, GLP Data Integrity. (oecd.org)